مؤتمر
HCVerso2: a phase III study of faldaprevir plus deleobuvir and ribavirin for chronic HCV genotype 1b infection in treatment naïve patients including those ineligible for pegylated interferon
| العنوان: | HCVerso2: a phase III study of faldaprevir plus deleobuvir and ribavirin for chronic HCV genotype 1b infection in treatment naïve patients including those ineligible for pegylated interferon |
|---|---|
| المؤلفون: | Nelson, D, Andreone, P, Colombo, M, Calinas, F, Olveira, A, DELWAIDE, Jean, Haussinger, D, Ouzan, D, Strasser, S, Asselah, T, Cooper, C, Stern, J, Boecher, W, Kukolj, G, Aslanyan, S, Deng, Q, Wang, E, Mensa, F |
| المصدر: | Hepatology, 60 (S1) (2014-10); The Liver Meeting 2014, du 7 novembre 2014 au 11 novembre 2014 |
| بيانات النشر: | Wiley, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Human health sciences, Gastroenterology & hepatology, Sciences de la santé humaine, Gastroentérologie & hépatologie |
| الوصف: | In treatment-naïve, non-cirrhotic patients with HCV GT1b infection, faldaprevir + deleobuvir + ribavirin for 16 or 24 w resulted in comparable SVR 12 rates (76% vs 82%) with similar tolerability profiles. Patients with cirrhosis achieved SVR 12 of 74% (24w). The adjusted SVR rates for 16 or 24w in patients with or without cirrhosis were significantly higher than historical control. |
| نوع الوثيقة: | conference paper http://purl.org/coar/resource_type/c_5794 conferenceObject peer reviewed |
| اللغة: | English |
| Relation: | urn:issn:0270-9139; urn:issn:1527-3350 |
| URL الوصول: | https://orbi.uliege.be/handle/2268/174728 |
| حقوق: | open access http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess |
| رقم الأكسشن: | edsorb.174728 |
| قاعدة البيانات: | ORBi |
| الوصف غير متاح. |